730360.fig.001
Figure 1: Schema of treatment regimens and associated cardiotoxicity in the large adjuvant trastuzumab trials. AC, doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, q3w; PTX, paclitaxel 175 mg/m2, q3w (NSABP B-31) or 80 mg/m2, qw (NCCTG N9831); HER, trastuzumab loading dose of 4 mg/kg followed by 2 mg/kg, qw (NSABP B-31, NCCTG N9831, and FinHER and in combination with DTX in BCIRG 06) or loading dose of 8 mg/kg followed by 6 mg/kg, q3w (HERA and PACS 04 and at trastuzumab alone phase in BCIRG 006); CTx, adjuvant and/or neoadjuvant chemotherapy; RT, adjuvant radiation therapy; DTX, docetaxel 100 mg/m2, q3w; TCH, docetaxel 75 mg/m2 and carboplatin area under the curve (AUC) 6, q3w and trastuzumab loading dose of 4 mg/kg followed by 2 mg/kg, qw; VNR, vinorelbine, 25 mg/m2, qw; FEC, fluorouracil 600 mg/m2, epirubicin 60 mg/m2, and cyclophosphamide 600 mg/m2, q3w (FinHER) or fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2, q3w (PACS 04); ED, epirubicin 75 mg/m2 and docetaxel 75 mg/m2, q3w; CHF, congestive heart failure; NR, not reported.